Angiotensin II receptor blockers as antiglaucoma agents
AssigneeSchering Corporation
InventorRobert W. Watkins
Life of this patent
Estimating the term…
Abstract
A method and composition for reducing and/or controlling elevated intraocular pressure, especially the elevated intraocular pressure associated with glaucoma, are disclosed in which an angiotensin II antagonist is administered to the eye.
Claims25
A method for reducing elevated intraocular pressure in a mammal which comprises topically administering to an eye of said mammal an intraocular pressure reducing amount of angiotensin II receptor blocker.
A kit comprising in separate containers in a single package pharmaceutical compositions for use in combination to reduce and control elevated intraocular pressure, which comprises in one container a pharmaceutical composition comprising an intraocular pressure reducing amount of an angiotensin II receptor blocker in a topical ophthamological carrier and in a second container a pharmaceutical composition comprising an intraocular pressure reducing amount of a beta-adrenergic blocking agent in a topical ophthamological carrier.
A kit comprising in separate containers in a single package pharmaceutical compositions for use in combination to reduce and control the elevated intraocular pressure associated with the use of steroidal anti-inflammatory agents in humans, which comprises in one container a pharmaceutical composition comprising an intraocular pressure reducing amount of an angiotension receptor blocker and in a second container, a pharmaceutical composition comprising an anti-inflammatory effective amount of a steroid in a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.